RCS - Yourgene Health PLC - Accelerator Phase Launch for Microdeletions Plugin

Yourgene HealthAnnouncement

24/05/2022 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220524:nRSX5162Ma&default-theme=true

RNS Number : 5162M  Yourgene Health PLC  24 May 2022

 

Yourgene Health plc

("Yourgene" or the "Company")

 

Launch of the Accelerator Phase for Microdeletions Plugin

Expanding the clinical menu and capabilities of IONA® Nx NIPT Workflow
offering

 

Manchester, UK - 24 May 2022: Yourgene (AIM: YGEN), a leading international
molecular diagnostics group, announces the launch of Yourgene's Accelerator
Phase for its Microdeletions(1) Plugin (the "Plugin"), which expands on the
clinical menu and capabilities of the class leading IONA® Nx NIPT Workflow
offering.

 

This Accelerator Phase follows a successful pilot project with a key partner
and IONA® Nx lab customer, LifeStrands Genomics, a leading clinical and
translational genomics group based in Singapore. This Accelerator Phase allows
the Company to collaborate with new laboratory partners or existing customers,
and is anticipated to run until later this year.

 

The analysis Plugin has been designed for use with the IONA® Nx NIPT Workflow
and is compatible within Yourgene's wider NIPT testing portfolio, broadening
the Company's offering. The Plugin tests for microdeletions ≥3Mb in size,
that are linked to a number of chromosomal syndromes including Di George,
Prader Willi & Angelman, 1p36 deletion, Cri du Chat and Wolf Hirschhorn
syndromes.

 

The IONA® Nx NIPT Workflow is an in vitro nucleic acid screening test that
measures the likelihood that a pregnant woman is carrying a fetus with Trisomy
13, 18 or 21, as well as optional additional chromosomal abnormalities. It is
a laboratory-based test that has been developed to run on the Illumina's
NextSeq 550Dx instrument, a next generation sequencing platform.

 

Lyn Rees, CEO of Yourgene Health said: "We are proud of the Microdeletions
Plugin as it builds on the advanced proprietary technology used to develop
IONA® Nx and provides an expanded offering enabling a more competitive NIPT
solution for our global laboratory customers. Yourgene is now one of a small
group of NIPT providers who include microdeletions in the workflow. We are
also pleased to launch this Accelerator Phase as we look to work with more
laboratory partners in the NIPT space. This represents a new era in Yourgene's
approach delivery of NIPT testing solutions, with a focus on 'Collaboration to
Perform' reflecting our focus on personalised healthcare."

 

(1) - A microdeletion is an abnormality that occurs when a piece of a
chromosome is missing

 

 

 

 Yourgene Health plc                              Tel: +44 (0)161 669 8122

 Lyn Rees, Chief Executive Officer                investors@yourgene-health.com (mailto:investors@yourgene-health.com)
 Barry Hextall, Chief Financial Officer
 Joanne Cross, Director of Marketing

 Singer Capital Markets (Joint Corporate Broker)  Tel: +44 (0)20 7496 3000
 Aubrey Powell / Tom Salvesen / George Tzimas

 Stifel Nicolaus Europe Limited (Joint Corporate Broker)                                 Tel: +44 (0)20 7710 7600
 Nicholas Moore / Matthew Blawat / Ben Maddison

 Walbrook PR Ltd (Media and Investor Relations)   Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com
 Paul McManus / Lianne Applegarth                 Mob: 07980 541 893 / Mob: 07584 391 303

 

 

About Yourgene Health

 

Yourgene Health is an international molecular diagnostics group which develops
and commercialises genetic products and services. The group works in
partnership with global leaders in DNA technology to advance diagnostic
science.

 

Yourgene primarily develops, manufactures, and commercialises simple and
accurate molecular diagnostic solutions, for reproductive health, precision
medicine and now infectious diseases. The Group's flagship products include
non-invasive prenatal tests (NIPT) for Down Syndrome and other genetic
disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests,
and a recent extension into the oncology space with DPYD genotyping.

 

The launch of Yourgene Genomic Services has enabled Yourgene to offer a global
laboratory service network equipped to be a full life-cycle partner for
clinical, research and pharmaceutical organisations to support partners at the
preclinical, clinical, and post-market stages to develop, manufacture, obtain
regulatory approval and commercialise new products and services. In addition,
Yourgene Genomic Services offers an NIPT and high throughput COVID testing
service.

 

In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation
technology company based in Vancouver, Canada, enabling the Company to extend
its offering and IP portfolio in the DNA sample preparation sector. The
acquisition increased Yourgene's geographical penetration into the US and
Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.

 

Yourgene Health is headquartered in Manchester, UK with offices in Taipei,
Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM
market under the ticker "YGEN". For more information visit
www.yourgene-health.com (http://www.yourgene-health.com/) and follow us on
twitter @Yourgene_Health.

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEAPSDAAXAEFA